Cabozantinib CAS:849217-68-1

Cabozantinib CAS:849217-68-1, sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Cabozantinib CAS:849217-68-1,marketed under the trade name Cabometyx among others, is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was discovered and developed by Exelixis Inc. Cabozantinib CAS:849217-68-1 was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011. Cabozantinib is approved by the U.S. FDA for medullary thyroid cancer. and advanced renal cell carcinoma in people who have received prior anti-angiogenic therapy. It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, and hepatocellular cancers. Cabozantinib CAS:849217-68-1 could be supplied in different size with competitive price.

Product Details

--2_01.png

Product Description

Name

High quality Cabozantinib CAS 849217-68-1

Other name

XL184;N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide;1,1-Cyclopropanedicarboxamide, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)

CAS

849217-68-1

Applications

API intermediates

Appearance

White powder

Cabozantinib CAS:849217-68-1, sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.

Cabozantinib CAS:849217-68-1,marketed under the trade name Cabometyx among others, is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was discovered and developed by Exelixis Inc.

Cabozantinib CAS:849217-68-1 was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011. Cabozantinib is approved by the U.S. FDA for medullary thyroid cancer. and advanced renal cell carcinoma in people who have received prior anti-angiogenic therapy. It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, and hepatocellular cancers.

Cabozantinib CAS:849217-68-1 could be supplied in different size with competitive price.

.jpg

Application

--2_04.png 

Related products
Main product
Company Information

--2_07.png--2_08.png--2_09.png--2_10.png--2_11.png

Packaging & Shipping

--2_12.png 

FAQ

Q1: Can I get some samples?
A: Yes, It is no problem.If you need sample ,please contact with us.
Q2: How to confirm the Product Quality before placing orders?
A:Firstly,we will send the sample for your testing and also provide our testing result.
Secondly,we could accept the third-party inspection.
Q3:What's your MOQ?
A:Normally,our MOQ is 1kg. But it could be according to your actual demandAny quantity is OK.
Q4: How about delivery time?
A:within 3-5 days after payment confirmed. (Chinese holiday not included)
Q5:Is there a discount?
A:Different quantity has different discount.
Q6: How do you treat quality complaint?
A:First of all, our quality control will ensure our quality in advance. If there is a real quality problem caused by us, we will provide good product again or refund your loss.--2_15.png


Hot Tags: cabozantinib cas:849217-68-1, China, suppliers, manufacturers, factory, wholesale, bulk

Inquiry

You Might Also Like